# A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants

> **NCT06651021** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 10 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** balcinrenone/dapagliflozin

## Key facts

- **NCT ID:** NCT06651021
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-21
- **Primary completion:** 2024-10-28
- **Final completion:** 2024-10-28
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06651021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06651021, "A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT06651021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*